Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/apt.17298 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of disease activity and quality of life of Korean patients with rheumatoid arthritis.
J Rheum Dis
January 2025
Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea.
The management of rheumatoid arthritis (RA) follows a treat-to-target approach, as recommended by guidelines from the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). RA treatment recommendations include an emphasis on frequent disease activity assessments to optimize therapy, recognizing the possibility of timely therapies to slow progression and improve long-term results. The evaluation of joint inflammation, pain, physical function, and clinical indicators is required for comprehensive RA therapy.
View Article and Find Full Text PDFEditorial: Treat-to-target in systemic lupus erythematosus: cytokine transduction pathways in SLE.
Front Immunol
October 2024
Department of Allergy, Immunology and Rheumatology, University of Rochester School of Medicine, Rochester, NY, United States.
Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1.
Lancet Diabetes Endocrinol
November 2024
Velocity Clinical Research at Medical City, Dallas, TX, USA.
Background: Continuous glucose monitoring (CGM) can provide a comprehensive assessment of glycaemic control. This exploratory analysis of the ONWARDS 1 trial assessed CGM-based metrics and CGM-derived hypoglycaemia duration in insulin-naive individuals with type 2 diabetes treated with subcutaneous once-weekly insulin icodec (icodec) versus once-daily insulin glargine U100 (glargine U100).
Methods: ONWARDS 1 was a 78-week (52-week main treatment phase and a 26-week treatment extension phase plus a 5-week follow-up), randomised, open-label, treat-to-target, phase 3a trial done at 143 sites (outpatient clinics and hospital departments) across 12 countries.
Application of disease activity index in rheumatoid arthritis management in Korea.
J Rheum Dis
October 2024
Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea.
Effective management of rheumatoid arthritis (RA) necessitates the accurate measurement of disease activity using a treat-to-target strategy established as a cornerstone approach. Disease activity assessment tools such as the Disease Activity Score in 28 joints (DAS28), Simplified Disease Activity Index, Clinical Disease Activity Index, and Routine Assessment of Patient Index Data 3 have been internationally validated and recognised. In Korea, the government initiated a quality assessment program mandating routine measurement of DAS28 to ensure high-quality RA management.
View Article and Find Full Text PDFPerformance of cut-offs of the ASAS Health Index to discriminate between treatment groups in patients with axial spondyloarthritis in the TICOSPA trial.
Semin Arthritis Rheum
December 2024
Rheumatologisches Versorgungszentrum Steglitz, Berlin, Germany.
Objective: To test trial and longitudinal known group discrimination of thresholds of meaning for improvement and health states of the ASAS Health Index (ASAS HI) in patients with active axSpA treated in a randomized study.
Methods: Data from baseline and week 48 from the tight-controlled, treat-to-target trial TICOSPA study were used. The performance of different thresholds to assess change or health states of the ASAS HI were evaluated between arms and against changes in patients' relevant outcomes and various external responder criteria.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!